Results of mutation status gene HER-2/NEU in patients with breast cancer in Ukraine

  • B. T. Klimuk
  • O. M. Dugan
  • A. V. Stefanovych
  • S. V. Klymenko
DOI: https://doi.org/10.7124/FEEO.v21.860

Abstract

Aim. Detection of changes in epidermal growth factor receptor 2 (HER-2/Neu) in tumor cells is critical to patient prognosis, prediction of response to standard chemotherapy, and perspectives for the treatment of anti-HER-2 therapy. Methods. The research study was conducted according to the recommendations of ASCO/CAP 2013 to diagnose cases of determining gene expression HER-2/Neu by FISH. To identify the exact status of the gene HER-2/Neu TP53 marker was selected. Results. A statistically significant difference (χ2 = 3.36, p>0.05) was found among the questionable cases of mutated HER-2 / neu in the patient groups which was surveyed according to 2007 and 2013 years recommendations. Conclusions. In comparison with 2007 ASCO/CAP 2007 (from 1.4 % to 4.2 %) 2013 ASCO/CAP showed more cases which was classified as doubtful during the test with two-color breakdown HER-2/CEP17.

Keywords: HER-2/Neu, mutation status, FISH, centromere area, TP53.

References

Limentani S.A., Brufsky A.M., Erban J.K., Jahanzeb M., Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery andadjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J. Clin. Oncol. 2007. V. 25. P. 1232–1238. doi: 10.1200/JCO.2005.05.3306.

Nitta H., Kelly B.D., Allred C., Jewell S., Banks P., Dennis E., Grogan T.M. The assessment of HER2 status in breast cancer: the past, the present, and the future [Elektronnyy resurs]. Pathology International. 2016. doi: 10.1111/pin.12407.

Fan Y.S., Casas C.E., Peng J., Watkins M., Fan L., Chapman J., Ikpatt O.F., Gomez C., Zhao W., Reis I.M. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Research and Treatment. 2016. V. 155(3). P. 457–462. doi: 10.1007/s10549-016-3717-z.

Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007. V. 25. P. 118–145. doi: 10.1200/JCO.2006.09.2775.

Hammond E.H., Wolff A.C., Hayes D.F., Schwartz J.N. Reply to Sauter G. et al.. J Clin Oncol. 2009. V. 27. P. 153–154. doi: 10.1200/JCO.2009.24.0366.

Hammond M.E., Hayes D.F., Wolff A.C. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011. V. 29. P. 458. doi: 10.1200/JCO.2011.35.2245

Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014. V. 138(2). P. 241-256. doi: 10.5858/arpa.2013-0953-SA

Hyun C.L., Lee H.E., Kim K.S., Kim S-W, Kim J.H., Choe G., Park S.Y. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J. Clin. Pathol. 2008. V. 61. P. 317-321. doi: 10.1136/jcp.2007.050336

Muller K.E., Marotti J.D., Memoli V.A., Wells W.A., Tafe L.J. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry. Am J Clin Pathol. 2013. V. 144. P. 247-252. doi: 10.1309/AJCPE5NCHWPSMR5D

Long T.H., Lawce H., Durum C., Moore S.R., Olson S.B., Gatter K., Troxell M.L. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines. Am J Clin Pathol. 2015. V. 144. P. 253-262. doi: 10.1309/AJCP3Q9WFOQTKUVV

Huiyong J., Xiaoyan B., Fanjun M., Cheng Z., Xuefeng Z. Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance. Oncol Lett. 2014. V. 7. P. 1954-1958. doi: 10.3892/ol.2014.2001

Kristen E. Muller D.O., Jonathan D., Marotti M.D., Vincent A., Memoli M.D., Wendy A., Wells M.D., Laura J., Tafe M.D. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry. American Journal of Clinical Pathology. 2015. V. 144. P. 247-252. doi: 10.1309/AJCPE5NCHWPSMR5D

Wells M.D., Laura J., Tafe M.D., Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry. American Journal of Clinical Pathology. 2015. V. 144(2). P. 247-252. doi: 10.1309/AJCPE5NCHWPSMR5D